Company: CRL
Filing Date: 2025-05-23
Form Type: 8-K
Source: 0001100682-25-000023
Chunk: 1

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-05-23
Form: 8-K
Item: Item 5.07
Chunk 1
---
 at the 2026 Annual Meeting of Shareholders.

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

         For        Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────
  40,218,870      1,432,240      102,252             2,209,405  

(c) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2024.

         For        Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────
  42,348,057      1,551,238       63,472                     0  

(e) The shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company.

        For         Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────
  3,457,547      38,051,509      244,306             2,209,405  

Computershare Trust Company, N. A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        CHARLES RIVER LABORATORIES INTERNATIONAL, INC.                   
  Date:      May 23, 2025      By:      /s/ Matthew L. Daniel                                            
                                        Matthew L. Daniel, Corporate Senior Vice President,              
                                        General Counsel, Corporate Secretary & Chief Compliance Officer